Afentakis, Maria, Dowsett, Mitch, Sestak, Ivana, Salter, Janine, Howell, Tony, Buzdar, Aman, Forbes, John, Cuzick, Jack. Springer New York LLC; 2013. Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.
Easton, Douglas F., Pooley, Karen A., the SEARCH collaborators,, Forbes, John, Devilee, Peter, Dunning, Alison M., Pharoah, Paul D. P., Thompson, Deborah, Ballinger, Dennis G., Struewing, Jeffrey P., Morrison, Jonathan, Field, Helen, Luben, Robert. Nature Publishing Group; 2007. Genome-wide association study identifies novel breast cancer susceptibility loci.
Dowsett, Mitch, Cuzick, Jack, Howell, Anthony, Bugarini, Roberto, Baehner, Frederick L., Shak, Steven, Wale, Christopher, Forbes, John, Mallon, Elizabeth A., Salter, Janine, Quinn, Emma, Dunbier, Anita, Baum, Michael, Buzdar, Aman. American Society of Clinical Oncology; 2010. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC Study.
Lee, Chee Khoon, Gebski, Val J., Coates, Alan S., Veillard, Anne-Sophie, Harvey, Vernon, Tattersall, Martin H. N., Byrne, Michael J., Brigham, Brian, Forbes, John, Simes, R. John. SpringerOpen; 2013. Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone.
Dowsett, Mitch, Cuzick, Jack, Coombes, Charles, Snowdon, Claire, Gnant, Michael, Jakesz, Raimund, Kaufmann, Manfred, Boccardo, Francesco, Godwin, Jon, Davies, Christina, Peto, Richard, Ingle, Jim, Coates, Alan, Forbes, John, Bliss, Judith, Buyse, Marc, Baum, Michael, Buzdar, Aman, Colleoni, Marco. American Society of Clinical Oncology; 2010. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.
Milne, Roger L., Kuchenbaecker, Karoline B., Jiang, Xia, Rostamianfar, Asha, Finucane, Hilary, Bolla, Manjeet K., McGuffog, Lesley, Wang, Qin, Aalfs, Cora M., ABCTB Investigators,, Braye, Stephen, Forbes, John, Michailidou, Kyriaki, Scott, Rodney J., Beesley, Jonathan, Kar, Siddhartha, Lindström, Sara, Hui, Shirley, Lemaçon, Audrey, Soucy, Penny, Dennis, Joe. Nature Publishing Group; 2017. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.
Dowsett, Mitch, Allred, Craig, Bishop, Hugh, Ellis, Ian, Larsimont, Danis, Sasano, Hironobu, Carder, Pauline, Cussac, Antonio L., Knox, Fiona, Speirs, Valerie, Forbes, John, Buzdar, Aman, Knox, Jill, Quinn, Emma, Salter, Janine, Wale, Chris, Cuzick, Jack, Houghton, Joan, Williams, Norman, Mallon, Elizabeth. American Society of Clinical Oncology; 2008. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial.